Reimagining Federal Policy Solutions for Employer Coverage of High- Cost Advanced Therapies
- Understanding how employer funded plans approach coverage, financial risk and policy decisions for high-cost cell and gene therapies
- Identifying federal policy options that could help stabilize employer risk exposure, including new payment models, reinsurance approaches, and regulatory pathways for value-based arrangements
- Exploring how federal policy can enable sustainable coverage of advanced therapies while protecting employer plan affordability and patient access